Cwm LLC Sells 1,487 Shares of Adaptive Biotechnologies Corporation $ADPT

Cwm LLC reduced its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 7.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,460 shares of the company’s stock after selling 1,487 shares during the period. Cwm LLC’s holdings in Adaptive Biotechnologies were worth $203,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in shares of Adaptive Biotechnologies by 36.5% in the first quarter. GAMMA Investing LLC now owns 13,393 shares of the company’s stock worth $100,000 after acquiring an additional 3,583 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in shares of Adaptive Biotechnologies in the first quarter worth $87,000. Diversified Trust Co bought a new position in shares of Adaptive Biotechnologies in the second quarter worth $438,000. Russell Investments Group Ltd. boosted its holdings in shares of Adaptive Biotechnologies by 104.7% in the first quarter. Russell Investments Group Ltd. now owns 165,831 shares of the company’s stock worth $1,232,000 after acquiring an additional 84,837 shares during the period. Finally, Blair William & Co. IL bought a new position in shares of Adaptive Biotechnologies in the first quarter worth $84,000. 99.17% of the stock is owned by institutional investors.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $16.90 on Wednesday. The firm has a market capitalization of $2.57 billion, a price-to-earnings ratio of -20.61 and a beta of 2.06. Adaptive Biotechnologies Corporation has a 52-week low of $4.27 and a 52-week high of $17.89. The stock has a fifty day moving average of $14.26 and a 200 day moving average of $11.56.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.07. Adaptive Biotechnologies had a negative return on equity of 60.93% and a negative net margin of 59.07%.The company had revenue of $49.94 million during the quarter, compared to analyst estimates of $49.40 million. During the same quarter last year, the company earned ($0.31) earnings per share. The firm’s quarterly revenue was up 36.3% on a year-over-year basis. Equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ADPT has been the subject of a number of analyst reports. Guggenheim initiated coverage on Adaptive Biotechnologies in a report on Tuesday, September 30th. They issued a “buy” rating and a $20.00 price target for the company. JPMorgan Chase & Co. raised their price target on Adaptive Biotechnologies from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Monday, October 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. BTIG Research raised their price target on Adaptive Biotechnologies from $14.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Finally, TD Cowen lifted their price objective on Adaptive Biotechnologies from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.22.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.